Defendant
15 cases as defendant.
Lupin Ltd. is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, India. Founded in 1968 by Desh Bandhu Gupta, it is a publicly traded company listed on the Bombay Stock Exchange (BSE: 500257) and the National Stock Exchange (NSE: LUPIN). As of May 2026, Lupin Ltd. has a market capitalization of approximately $10.76 billion to $10.9 billion USD and employs over 24,000 people globally. The company reported a revenue of approximately $2.81 billion USD for the twelve months ending in 2025. The Gupta family, as the promoter group, retains significant influence with approximately 46.86% of the shares as of March 2026.
Lupin is primarily engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. Its diverse portfolio includes branded and generic formulations, complex generics, biotechnology products (biosimilars), and active pharmaceutical ingredients (APIs). The company's therapeutic focus areas span pediatrics, cardiovascular, anti-infectives, diabetology, asthma, anti-tuberculosis, respiratory, women's health, and central nervous system disorders. Lupin operates globally, with a significant presence in markets such as the United States, Europe, Japan, Australia, and emerging economies.
In terms of patent litigation, Lupin Ltd. appears to operate as a defending company. The provided case data shows one instance where Lupin Ltd. is listed as a defendant and zero as a plaintiff. This indicates that the company is primarily a target of patent infringement allegations rather than an entity actively asserting its own patent portfolio.
The sole tracked case involving Lupin Ltd. is "Otsuka Pharmaceutical Co., Ltd. v. Lupin Ltd. et al.," where Lupin Ltd. is a defendant. This case is being litigated in the U.S. District Court for the District of Delaware.
Neurelis, Inc.'s ANDA suit against Lupin entities. Aggregator pages list the '664 patent among the consolidated Neurelis ANDA family, but the individual docket has not been independently confirmed to assert it.
Jazz Pharmaceuticals Ireland Ltd. sued Lupin Ltd. in the District of New Jersey. The case was filed 2023-01-20 and terminated 2023-02-16.
Jazz sued Lupin over Lupin's ANDA No. 215911 for generic Xywav; the complaint expressly lists the '426 patent among ten patents-in-suit. Lupin answered and counterclaimed; the case was consolidated with later Lupin suits and the Teva action, with no final merits judgment on the '426 patent found.
Hatch-Waxman ANDA infringement action by Sun against Lupin concerning Lupin's ANDA No. 211239 for bromfenac ophthalmic solution 0.075%. The court found the ’999 patent not literally infringed, obvious, and indefinite, but the case was settled and dismissed with prejudice in February 2022, with the September 30, 2021 opinion vacated.
ANDA Hatch-Waxman action by Jazz Pharmaceuticals and others against Lupin Ltd. and others involving Xyrem and US 7,765,107. Complaint filed September 1, 2015; case terminated January 15, 2016.
Jazz Pharmaceuticals, Inc. et al. sued Lupin entities in D.N.J. involving the '106 patent. The case was closed and later settled June 12, 2018 per Hagens Berman complaint; docket noted termination Jan. 15, 2016 per L. Civ. R. 11.2 certification.
The District Court found Lupin did not infringe US Patent 8501730 and US Patent 8273735, with US Patent 8273735 also found invalid as obvious. On appeal, the Federal Circuit affirmed the non-infringement finding for 8501730, but controversially determined its asserted method claims were invalid as obvious.
Action asserting the '708 patent; settled.
Case noted for disambiguation because it involved U.S. 8,778,999, a bromfenac/Bromsite patent different from 6,030,999.
D.N.J. Hatch-Waxman/ANDA litigation over Xyrem. Jazz's mandatory notices in IPR2015-01903 identify the '963 patent as asserted in this action.
The '306 patent was asserted against Lupin. The case settled on June 12, 2018, as described in antitrust complaints.
Complaint expressly lists the '306 patent among the patents-in-suit. Status not confirmed.
Filed after Lupin's July 23, 2015 Paragraph IV notice. The complaint confirms the '650 patent as a patent-in-suit; settled.
Lupin action consolidated into the Jazz v. Amneal consolidated litigation, 2:13-cv-00391.
Celgene asserted the '800 and '217 patents against Lupin over lenalidomide ANDA products. The case settled.